Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
We examined the effect of intravenously infused glucagon-like peptide 1 (GLP-1) on subjective appetite sensations after an energy-fixed breakfast, and on spontaneous energy intake at an ad libitum lunch. 20 young, healthy, normal-weight men participated in a placebo-controlled, randomized, blinded, crossover study. Infusion (GLP-1, 50 pmol/ kg.h or saline) was started simultaneously with initiation of the test meals. Visual analogue scales were used to assess appetite sensations throughout the experiment and the palatability of the test meals. Blood was sampled throughout the day for analysis of plasma hormone and substrate levels. After the energy-fixed breakfast, GLP-1 infusion enhanced satiety and fullness compared with placebo (treatment effect: P < 0.03). Furthermore, spontaneous energy intake at the ad libitum lunch was reduced by 12% by GLP-1 infusion compared with saline (P = 0.002). Plasma GLP-1, insulin, glucagon, and blood glucose profiles were affected significantly by the treatment (P < 0.002). In conclusion, the results show that GLP-1 enhanced satiety and reduced energy intake and thus may play a physiological regulatory role in controlling appetite and energy intake in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1 RA increase satiety, reduce food intake and delay gastric emptying whilst they also stimulate insulin release and inhibit glucagon secretion in a glucose-dependent manner (Fig. 1) [17, 18].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Short-term studies have demonstrated that glucagon-like peptide-1 receptor agonists (GLP-1RA) induce weight loss by promoting satiety and reducing hunger16–19.”
From Exploratory analysis of eating-and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment (2022) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, non-clinical and clinical studies have demonstrated increased satiety, reduced food intake and subsequent reductions in body weight following administration of GLP-1,7, 8”
From Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults (2014) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Among the two incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), the latter has been established as having therapeutic potential for reducing elevated plasma glucose (1, 2) and body weight (3), while the former has been unable to either stimulate insulin secretion (1) or lower plasma glucose effectively in type 2 diabetes (T2D) (4).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [3]
In the citing paper
“GLP-1 receptor agonists (GLP-1RA) have been shown to promote weight loss and decrease liver fat [28,29] (Figure 1).”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [29]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1975) · Journal of AOAC INTERNATIONAL · doi:10.1093/jaoac/58.5.1085 · Cited by 19,795
(1974) · Elsevier eBooks · doi:10.1016/b978-0-12-091304-6.x5001-0 · Cited by 6,755
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
Self-citationTissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 919
Self-citationInduction of intestinal epithelial proliferation by glucagon-like peptide 2.
Drucker, D. J., Erlich, P., Asa, S. L., & Brubaker, P. L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.15.7911 · Cited by 880
Nauck, M. A., Niedereichholz, U., Ettler, R., Holst, J. J., Ørskov, C., Ritzel, R., & Schmiegel, W. H. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.5.e981 · Cited by 817
Self-citationScrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793
Mojsov, S., Heinrich, G., Wilson, I. B., Ravazzola, M., Orci, L., & Habener, J. F. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)67324-7 · Cited by 724
Cited by
Items 201–300 of 1,003
Trapp, S., & Brierley, D. I. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15638 · Cited by 154
“This occurs in human patients as well as in animal models (Flint et al., 1998; Wilding et al., 2021; Williams et al., 2009).”
BackgroundVallöf, D., Maccioni, P., Colombo, G., Mandrapa, M., Jörnulf, J. W., Egecioglu, E., Engel, J. A., & Jerlhag, E. (2016) · Addiction Biology · doi:10.1111/adb.12295 · Cited by 150
Glucagon-like Peptide-1: The Basis of a New Class of Treatment for Type 2 Diabetes
Knudsen, L. B. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030630m · Cited by 154
Neuroprotective properties of GLP-1: theoretical and practical applications
Holst, J. J., Burcelin, R., & Nathanson, E. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.549466 · Cited by 150
Self-citationPannacciulli, N., Le, D. S. N. T., Salbe, A. D., Chen, K., Reiman, E. M., Tataranni, P. A., & Krakoff, J. A. (2007) · NeuroImage · doi:10.1016/j.neuroimage.2006.12.035 · Cited by 182
“Short-term GLP-1 administration is associated with increased feelings of fullness paralleled by decreased appetite in humans (Flint et al., 1998).”
BackgroundAppetite and Cancer-Associated Anorexia: A Review
Davis, M. P., Dreicer, R., Walsh, D., Lagman, R. L., & LeGrand, S. B. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.103 · Cited by 155
van Bloemendaal, L., Veltman, D. J., ten Kulve, J. S., Groot, P. F. C., Ruhé, H. G., Barkhof, F., Sloan, J. H., Diamant, M., & Ijzerman, R. G. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12506 · Cited by 151
“We found no statistically significant effects of GLP-1 receptor activation on hunger, fullness, appetite, prospective food consumption and desire to eat scores, which is in contrast to previous studies [9].”
BackgroundResultGibbons, C., Blundell, J., Tetens Hoff, S., Dahl, K., Bauer, R., & Bækdal, T. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14255 · Cited by 149
“reduction were investigated, increased satiety and reduced food intake were observed.(3,4) From animal studies, it appears that functional GLP-1 receptors in specific parts of the brain are required for weight loss.”
BackgroundLee, A., Patrick, P., Wishart, J., Horowitz, M., & Morley, J. E. (2002) · Diabetes, Obesity and Metabolism · doi:10.1046/j.1463-1326.2002.00219.x · Cited by 150
From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy
Holst, J. J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00260 · Cited by 147
“But were these observations relevant for peripheral GLP1? Would peripheral GLP-1 be able to reach nuclei in the brain and what might be the effect of this? It was soon demonstrated that leaks in the blood barrier notably in the area postrema, the subfornical organ and themedian eminence would not only allow entry of G…”
BackgroundSelf-citationLund, A., Knop, F. K., & Vilsbøll, T. (2014) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2014.03.005 · Cited by 164
“GLP-1 also promotes satiety [24] presumably mediated by a combination of central (GLP-1 can access the brain via leaks in the blood–brain barrier) and peripheral (possibly by affecting vagal afferent fibres)”
BackgroundHellström, P. M., Geliebter, A., Näslund, E., Schmidt, P. T., Yahav, E. K., Hashim, S. A., & Yeomans, M. R. (2004) · British Journal of Nutrition · doi:10.1079/bjn20041142 · Cited by 149
“…subjects, most, but not all (Long et al. 1999), studies report decreased food intake after administration of GLP-1, including studies in normal weight, diabetic and obese subjects (Flint et al. 1998, 2000; Näslund et al. 1998b, 1999b; Gutzwiller et al. 1999a,b; Toft-Nielsen et al. 1999) (Fig.”
BackgroundFeinglos, M. N., Saad, M. F., Pi‐Sunyer, F. X., An, B., Santiago, O., & on behalf of the Liraglutide Dose‐Response Study Group (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01567.x · Cited by 151
The role of glucagon‐like peptide‐1 impairment in obesity and potential therapeutic implications
Madsbad, S. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12119 · Cited by 146
“GLP-1 is also a physiological regulator of food intake and appetite, increasing satiety and reducing hunger, and thereby exerting an anorectic effect [35,36,41,42].”
BackgroundResultThe physiological role of GLP-1 in human: incretin, ileal brake or more?
Schirra, J. R. J., & Göke, B. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2004.06.018 · Cited by 166
John, G., Wang, L., Nanavati, J., Twose, C., Singh, R., & Mullin, G. (2018) · Genes · doi:10.3390/genes9030167 · Cited by 145
“gastric emptying and centrally promoting satiation [7].”
BackgroundPasman, W. J., Heimerikx, J., Rubingh, C. M., van den Berg, R., O’Shea, M., Gambelli, L., Hendriks, H., Einerhand, A. W. C., Scott, C. E., Keizer, H. G., et al. (2008) · Lipids in Health and Disease · doi:10.1186/1476-511x-7-10 · Cited by 151
Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists
Saraiva, F. K., & Sposito, A. C. (2014) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0142-7 · Cited by 143
“This effect seems to be very important for the normalization of postprandial glucose (PPG) elevations, and potentially even more important than the insulinotropic effects of GLP-1 for maintaining PPG homeostasis [19].”
BackgroundGlucagon-like peptide-1: a major regulator of pancreatic beta-cell function
Perfetti, R., & Merkel, P. (2000) · European Journal of Endocrinology · doi:10.1530/eje.0.1430717 · Cited by 143
“Hypothalamus Promotion of satiety Present (41, 42 ) Not-determined Preserved (19) Preserved (43) Other tissues (fat, muscle, liver) Increase of insulin sensitivity/glucose disposal Presence of conflicting reports (20, 44, 45, 47, 49, 50, 52, 53) Conflicting reports (20) Not determined Conflicting reports (20, 48, 51)…”
BackgroundBergmann, N. C., Lund, A., Gasbjerg, L. S., Meessen, E. C. E., Andersen, M. M., Bergmann, S., Hartmann, B., Holst, J. J., Jessen, L., Christensen, M. B., et al. (2019) · Diabetologia · doi:10.1007/s00125-018-4810-0 · Cited by 142
Self-citationLearning one’s genetic risk changes physiology independent of actual genetic risk
Turnwald, B. P., Goyer, J. P., Boles, D. Z., Silder, A., Delp, S. L., & Crum, A. J. (2018) · Nature Human Behaviour · doi:10.1038/s41562-018-0483-4 · Cited by 142
Pharmacological management of appetite expression in obesity
Halford, J. C. G., Boyland, E. J., Blundell, J. E., Kirkham, T. C., & Harrold, J. A. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.19 · Cited by 156
“…hunger Table 1 | Effects of GLP-1, GLP-1 analogs and related peptides on appetite expression study Participants and peptide effect on appetite Flint et al. (1998)100 20 normal-weight men GLP-1 (50 pmol/kg/h) 12% reduction in caloric intake at test meal Reduction in premeal hunger and…”
Hui, H., Farilla, L., Merkel, P., & Perfetti, R. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1460863 · Cited by 143
Nutritional modulation of endogenous glucagon-like peptide-1 secretion: a review
Bodnaruc, A. M., Prud’homme, D., Blanchet, R., & Giroux, I. (2016) · Nutrition & Metabolism · doi:10.1186/s12986-016-0153-3 · Cited by 139
The Enteroinsular Axis and the Recovery from Type 2 Diabetes after Bariatric Surgery
Patriti, A., Facchiano, E., Sanna, A., Gullà, N., & Donini, A. (2004) · Obesity Surgery · doi:10.1381/0960892041590818 · Cited by 149
Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management
Sinha, R., Papamargaritis, D., Sargeant, J. A., & Davies, M. J. (2023) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes22067 · Cited by 138
Physiological effects of dietary fructans extracted from Agave tequilana Gto. and Dasylirion spp.
Urías-Silvas, J. E., Cani, P. D., Delmée, E., Neyrinck, A., López, M. G., & Delzenne, N. M. (2008) · British Journal of Nutrition · doi:10.1017/s0007114507795338 · Cited by 137
Peripheral Interaction of Ghrelin with Cholecystokinin on Feeding Regulation
Date, Y., Toshinai, K., Koda, S., Miyazato, M., Shimbara, T., Tsuruta, T., Niijima, A., Kangawa, K., & Nakazato, M. (2005) · Endocrinology · doi:10.1210/en.2004-1240 · Cited by 139
Balasubramanian, R., Schneider, E., Gunnigle, E., Cotter, P. D., & Cryan, J. F. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105562 · Cited by 152
“The patterns of endogenous and exogenous release of GLP-1 have been well reported in murine models and human studies (Flint et al., 1998; Terrill et al., 2019; Chen et al., 2021a) and therefore can be adopted to study the effects of fermented foods on satiation.”
Reproducibility and power of ad libitum energy intake assessed by repeated single meals
Gregersen, N. T., Flint, A., Bitz, C., Blundell, J. E., Raben, A., & Astrup, A. V. (2008) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/87.5.1277 · Cited by 159
“A number of appetite hormones (eg, glucagon-like peptide 1) have been examined on the basis of subjective appetite recordings with the use of visual analogue scales (VAS) and ad libitum energy intake (EI) and have subsequently been shown to influence appetite and food intake (1, 2).”
MethodSelf-citationAdam, T. C. M., & Westerterp-Plantenga, M. S. (2005) · British Journal of Nutrition · doi:10.1079/bjn20041335 · Cited by 136
“GLP-1 has been shown to reduce energy intake, enhance sensations of fullness and decrease feelings of hunger in lean (Flint et al. 1998) as well as in obese (Näslund et al.”
BackgroundInfluentialRatliff, J. C., Leite, J. O. M., de Ogburn, R., Puglisi, M. J., VanHeest, J. L., & Fernández, M. L. (2010) · Nutrition Research · doi:10.1016/j.nutres.2010.01.002 · Cited by 150
“Flint et al [39] found that plasma GLP-1 concentrations of ~80 pmol/ L are able to exert suppressive effects on appetite after GLP1 infusion.”
BackgroundOptimal prandial timing of bolus insulin in diabetes management: a review
Slattery, D., Amiel, S. A., & Choudhary, P. (2018) · Diabetic Medicine · doi:10.1111/dme.13525 · Cited by 132
Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives
Meier, J. J., Gallwitz, B., Schmidt, W. E., & Nauck, M. A. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01434-6 · Cited by 146
Obesity: A Review of Pathogenesis and Management Strategies
Kaila, B., & Raman, M. (2008) · Canadian Journal of Gastroenterology · doi:10.1155/2008/609039 · Cited by 128
Regional brain response to visual food cues is a marker of satiety that predicts food choice
Mehta, S. H., Melhorn, S. J., Smeraglio, A., Tyagi, V., Grabowski, T. J., Schwartz, M. W., & Schur, E. A. (2012) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.112.042341 · Cited by 141
Luginbuhl, K. M., Schaal, J. L., Umstead, B. R., Mastria, E. M., Li, X., Banskota, S., Arnold, S., Feinglos, M. N., D’Alessio, D. A., & Chilkoti, A. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-017-0078 · Cited by 130
“Wild-type GLP1 is comprised of amino acids 7–37; by convention, the initial, N-terminal His residue is numbered seven as a result of its initial discovery as a longer proglucagon fragment whose initial six residues are cleaved during further processing in the gut 63 .”
Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases
Clemmensen, C., Finan, B., Müller, T. D., DiMarchi, R. D., Tschöp, M. H., & Hofmann, S. M. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0118-x · Cited by 134
Holst, J. J. (1999) · Trends in Endocrinology and Metabolism · doi:10.1016/s1043-2760(99)00157-5 · Cited by 146
Self-citationGlucagon-Like Peptide-1 Is Involved in Sodium and Water Homeostasis in Humans
Gutzwiller, J.-P., Hruz, P., Huber, A. R., Hamel, C., Zehnder, C., Drewe, J., Gutmann, H., Stanga, Z., Vogel, D., & Beglinger, C. (2006) · Digestion · doi:10.1159/000094334 · Cited by 127
“GLP-1 is one of the mediators of this effect and has been proposed to play a physiological regulatory role in controlling appetite and energy intake in health and disease [”
BackgroundSeino, Y., Terauchi, Y., Osonoi, T., Yabe, D., Abe, N., Nishida, T., Zacho, J., & Kaneko, S. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13082 · Cited by 127
Neuroactive Peptides as Putative Mediators of Antiepileptic Ketogenic Diets
Giordano, C., Marchiò, M., Timofeeva, E., & Biagini, G. (2014) · Frontiers in Neurology · doi:10.3389/fneur.2014.00063 · Cited by 128
“Appetite-reducing peptides released by the gut include cholecystokinin (CCK) (99, 100), glucagon-like peptide-1 (GLP-1) (101, 102), peptide YY (PYY) (103, 104), and oxyntomodulin (105, 106).”
BackgroundKabahizi, A., Wallace, B., Lieu, L., Chau, D., Dong, Y., Hwang, E., & Williams, K. W. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15682 · Cited by 126
“…effects are shared across species from rodents to humans, as peripheral GLP-1 administration to normal and diabetic human subjects induced satiety and reduced food intake in short term studies (Flint et al., 1998; Gutzwiller et al., 1999; Toft-Nielsen et al., 1999; Verdich et al., 2001).”
BackgroundThe Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease
Romero, F. A., Jones, C. T., Xu, Y., Fenaux, M., & Halcomb, R. L. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01701 · Cited by 120
A concise review on the therapeutics of obesity
Bray, G. A. (2000) · Nutrition · doi:10.1016/s0899-9007(00)00424-x · Cited by 143
GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management
Holst, J. J. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01113-9 · Cited by 125
“43), and, even in such limited amounts, GLP-1 caused a clear inhibition of interprandial sensations of hunger and satiety as well as food intake.”
Self-citationAmato, A., Cinci, L., Rotondo, A., Serio, R., Faussone-pellegrini, M. S., Vannucchi, M. G., & Mulè, F. (2010) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2010.01476.x · Cited by 124
Glucagon-like peptide 2 function in domestic animals
Burrin, D. G., Stoll, B., & Guan, X. (2003) · Domestic Animal Endocrinology · doi:10.1016/s0739-7240(02)00210-2 · Cited by 146
“However, studies in humans showed that intravenous infusion of GLP-1 prior to a meal promoted satiety and suppressed energy intake [125,126].”
BackgroundObesity-associated biomarkers and executive function in children
Miller, A. L., Lee, H. J., & Lumeng, J. C. (2015) · Pediatric Research · doi:10.1038/pr.2014.158 · Cited by 122
“Glucagon-like peptide 1 (secreted by the intestine) is another appetite-regulating hormone that promotes satiety and decreases energy intake (21) and is reduced in obesity (22).”
Nutrient detection by incretin hormone secreting cells
Diakogiannaki, E., Gribble, F. M., & Reimann, F. (2012) · Physiology & Behavior · doi:10.1016/j.physbeh.2011.12.001 · Cited by 123
Incretin Hormones and Type 2 Diabetes—Mechanistic Insights and Therapeutic Approaches
Boer, G. A., & Holst, J. J. (2020) · Biology · doi:10.3390/biology9120473 · Cited by 153
Self-citationEvaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists
Gasbjerg, L. S., Bergmann, N. C., Stensen, S., Christensen, M. B., Rosenkilde, M. M., Holst, J. J., Nauck, M., & Knop, F. K. (2020) · Peptides · doi:10.1016/j.peptides.2019.170183 · Cited by 121
Self-citationLong, S. J., Hart, K., & Morgan, L. M. (2002) · British Journal of Nutrition · doi:10.1079/bjn2002560 · Cited by 121
Hornby, C., Mollan, S. P., Botfield, H. F., O’Reilly, M., & Sinclair, A. J. (2018) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000000684 · Cited by 131
Weight neutrality with the DPP-4 inhibitor, vildagliptin: Mechanistic basis and clinical experience
Foley (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s10952 · Cited by 119
Dietary Fiber in the Prevention and Treatment of Metabolic Syndrome: A Review
Aleixandre, A., & Miguel, M. (2008) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408390701761886 · Cited by 138
Iepsen, E. W., Lundgren, J., Dirksen, C., Jensen, J.-E., Pedersen, O., Hansen, T., Madsbad, S., Holst, J. J., & Torekov, S. S. (2015) · International Journal of Obesity · doi:10.1038/ijo.2014.177 · Cited by 118
Self-citationKapitza, C., Dahl, K., Jacobsen, J. B., Axelsen, M. B., & Flint, A. (2017) · Diabetologia · doi:10.1007/s00125-017-4289-0 · Cited by 117
“In another study, liraglutide restored beta cell responsiveness to glucose during a stepwise glucose clamp [11], which is in line with trials showing glucose-dependent insulin secretion [12], decreased glucagon secretion from pancreatic islets [12, 13] and delayed gastric emptying [14, 15].”
ResultSelf-citationThe effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans
Flint, A., Raben, A., Rehfeld, J. F., Holst, J. J., & Astrup, A. V. (2000) · International Journal of Obesity · doi:10.1038/sj.ijo.0801126 · Cited by 130
Self-citationDiabesity: therapeutic options
Colagiuri, S. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01182.x · Cited by 118
“They slow gastric emptying and increase satiety, mechanisms that are in part responsible for the weight loss associated with this class [54,88,89].”
BackgroundEating behavior in the Old Order Amish: heritability analysis and a genome-wide linkage analysis
Steinle, N., Hsueh, W., Snitker, S., Pollin, T. I., Sakul, H., Jean, P. L. S., Bell, C. J., Mitchell, B. D., & Shuldiner, A. R. (2002) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/75.6.1098 · Cited by 131
Peripheral administration of GLP-2 to humans has no effect on gastric emptying or satiety
Schmidt, P. T., Näslund, E. B., Grybäck, P., Jacobsson, H., Hartmann, B., Holst, J. J., & Hellström, P. M. (2003) · Regulatory Peptides · doi:10.1016/s0167-0115(03)00175-7 · Cited by 116
Self-citationThe GLP-1 journey: from discovery science to therapeutic impact
Drucker, D. J. (2024) · Journal of Clinical Investigation · doi:10.1172/jci175634 · Cited by 126
“GLP-1 infusion increased sensations of fullness and satiety and reduced solid food intake after breakfast and lunch (8).”
Consumption of sugars and the regulation of short-term satiety and food intake
Anderson, G. H., & Woodend, D. (2003) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/78.4.843s · Cited by 134
The glucagon-like peptides: a double-edged therapeutic sword?
Perry, T., & Greig, N. H. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(03)00160-3 · Cited by 122
Gastrointestinal satiety signals in humans — Physiologic roles for GLP-1 and PYY ?
Beglinger, C., & Degen, L. P. (2006) · Physiology & Behavior · doi:10.1016/j.physbeh.2006.05.048 · Cited by 117
Swithers, S. E., Laboy, A. F., Clark, K., Cooper, S., & Davidson, T. L. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.04.024 · Cited by 113
Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins
Ansar, S., Koska, J., & Reaven, P. D. (2011) · Cardiovascular Diabetology · doi:10.1186/1475-2840-10-61 · Cited by 112
“GLP-1 also reduces glucose concentrations through inhibition of pancreatic a-cell glucagon secretion and indirectly via inhibition of gastric emptying and appetite [73-75].”
BackgroundGLP-1 Induces Barrier Protective Expression in Brunnerʼs Glands and Regulates Colonic Inflammation
Bang-Berthelsen, C. H., Holm, T. L., Pyke, C., Simonsen, L., Søkilde, R., Pociot, F., Heller, R. S., Folkersen, L., Kvist, P. H., Jackerott, M., et al. (2016) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000847 · Cited by 111
“GLP-1 also suppresses energy intake, which subsequently leads to weight loss.(6) Recent reports in mice focus on the local role of GLP-1 and GLP-2 receptors in the GI tract where GLP-1 and GLP-2 have”
BackgroundBoyd, K. A., O'Donovan, D. G., Doran, S., Wishart, J., Chapman, I. M., Horowitz, M., & Feinle, C. (2003) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00375.2002 · Cited by 113
Reimer, R. A. (2006) · Journal of Endocrinology · doi:10.1677/joe.1.06557 · Cited by 112
“In addition to potentiating glucosedependent insulin secretion, GLP-1 stimulates proinsulin gene expression and biosynthesis (Drucker et al. 1987) and reduces food intake through interactions with the hypothalamus (Turton et al. 1996, Flint et al. 1998).”
BackgroundAnti-obesity drugs: a critical review of current therapies and future opportunities
Clapham, J. C., Arch, J. R., & Tadayyon, M. (2001) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(00)00105-4 · Cited by 120
GLP-1, the Gut-Brain, and Brain-Periphery Axes
Cabou, C., & Burcelin, R. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.418 · Cited by 110
“These properties were also demonstrated in clinical studies: an intravenous GLP-1 infusion both decreased food intake and increased satiety in healthy [81], diabetic [82], and obese [83] subjects.”
BackgroundParkes, D. G., Mace, K. F., & Trautmann, M. E. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.741580 · Cited by 108
“2 GLP-1 and the GLP-1 receptor GLP-1 is rapidly secreted by the L-cells of the intestinal mucosa in response to nutrient ingestion directly into the hepatic portal circulation where a glucose sensor is located [11,13-19].”
BackgroundMin, J. S., Jo, S. J., Lee, S., Kim, D. Y., Kim, D. H., Lee, C. B., & Bae, S. K. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s506957 · Cited by 132
“16,17 The appetite-regulating effects of GLP-1 RAs are primarily mediated by both peripheral (vagal) and central nervous system pathways.”
Appetite: Measurement and Manipulation Misgivings
Mattes, R. D., Hollis, J., Hayes, D., & Stunkard, A. J. (2005) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2005.02.029 · Cited by 134
ten Kulve, J. S., Veltman, D. J., van Bloemendaal, L., Barkhof, F., Deacon, C. F., Holst, J. J., Konrad, R. J., Sloan, J. H., Drent, M. L., Diamant, M., et al. (2015) · Diabetologia · doi:10.1007/s00125-015-3754-x · Cited by 109
Self-citationTargeting β-Cell Function Early in the Course of Therapy for Type 2 Diabetes Mellitus
Leahy, J. L., Hirsch, I. B., Peterson, K. A., & Schneider, D. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0668 · Cited by 108
Rodbard, H. W., Bode, B. W., Harris, S. B., Rose, L., Lehmann, L., Jarlov, H., Thurman, J., & the Dual Action of Liraglutide and insulin degludec (DUAL) IV trial investigators (2017) · Diabetic Medicine · doi:10.1111/dme.13256 · Cited by 109
Convergence between biological, behavioural and genetic determinants of obesity
Ghosh, S., & Bouchard, C. (2017) · Nature Reviews Genetics · doi:10.1038/nrg.2017.72 · Cited by 124
Ulrich-Lai, Y. M., & Ryan, K. K. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.01.020 · Cited by 104
“It acts at its receptor (GLP-1R) to augment insulin secretion from pancreatic b cells, facilitating normal glucose tolerance (Baggio and Drucker, 2007; Holst, 2007), and it promotes satiety in both rodents and humans (Flint et al., 1998; Turton et al., 1996).”
Nagell, C. F., Wettergren, A., Pedersen, J. F., Mortensen, D., & Holst, J. J. (2004) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520410004424 · Cited by 108
“In addition, GLP-1 reduces appetite and food intake, and may therefore act as one of the intestinal factors responsible for postprandial satiation (5).”
BackgroundSelf-citationIncretin-Based Therapies: Review of Current Clinical Trial Data
Peters, A. L. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.12.007 · Cited by 119
Localization of orexin-1 receptors to vagal afferent neurons in the rat and humans
Burdyga, G., Lal, S., Spiller, D. G., Jiang, W. Y., Thompson, D. G., Attwood, S. E., Saeed, S. R., Grundy, D., Varró, A., Dimaline, R., et al. (2003) · Gastroenterology · doi:10.1053/gast.2003.50020 · Cited by 108
Targeting β-Cell Mass in Type 2 Diabetes: Promise and Limitations of New Drugs Based on Incretins
Salehi, M., Aulinger, B. A., & D'Alessio, D. A. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0031 · Cited by 109
Review article: a comparison of glucagon‐like peptides 1 and 2
Janssen, P., Rotondo, A., Mulé, F., & Tack, J. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12092 · Cited by 105
Nutrient-Induced Cellular Mechanisms of Gut Hormone Secretion
Lu, V. B., Gribble, F. M., & Reimann, F. (2021) · Nutrients · doi:10.3390/nu13030883 · Cited by 117
Targeting the incretin system in obesity and type 2 diabetes mellitus
Ansari, S., Khoo, B. C. E., & Tan, T. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-00979-9 · Cited by 127
Bray, G. A. (2001) · Reviews in Endocrine and Metabolic Disorders · doi:10.1023/a:1011808701117 · Cited by 122
“A fragment of glucagon (amino acids 6-29) called glucagon-like peptide-1 (GLP-1) reduced food intake when given either peripherally [69] or injected into the brain.”
BackgroundVeldhorst, M. A. B., Nieuwenhuizen, A. G., Hochstenbach-Waelen, A., Westerterp, K. R., Engelen, M. P. K. J., Brummer, R.-J. M., Deutz, N. E. P., & Westerterp-Plantenga, M. S. (2009) · Clinical Nutrition · doi:10.1016/j.clnu.2008.12.003 · Cited by 104
Johansson, E. V., Nilsson, A. C., Östman, E. M., & Björck, I. M. E. (2013) · Nutrition Journal · doi:10.1186/1475-2891-12-46 · Cited by 103
“Previously it has been found that intravenous infusions of GLP-1 (50 pmol/kg⋅h) during 4 h reduced voluntary energy intake by 12% at a subsequent lunch meal, as compared to saline in young healthy men [39].”
BackgroundGLP‐1 agonists for obesity and type 2 diabetes in children: Systematic review and meta‐analysis
Chadda, K. R., Cheng, T. S., & Ong, K. K. (2021) · Obesity Reviews · doi:10.1111/obr.13177 · Cited by 103
“Furthermore, GLP-1 delays gastric emptying, promotes satiety, and reduces food intake,(13) potentially leading to weight loss.(11,14,15) In adults, meta-analyses of randomized controlled trials (RCTs) of GLP-1 agonists in patients with T2DM and/or obesity have shown benefits on glycemic control and weight loss.”
BackgroundHomeostatic regulation of food intake
Cifuentes, L., & Acosta, A. J. (2021) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2021.101794 · Cited by 132
Neural regulation of glucagon-like peptide-1 secretion in pigs
Hansen, L., Lampert, S., Mineo, H., & Holst, J. J. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00197.2004 · Cited by 107
“Thus infusions of GLP-1 have been shown to reduce appetite and energy intake in humans (14).”
BackgroundSelf-citationTreatment of Type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors
Holst, J. J. (2004) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.9.1.155 · Cited by 103
Self-citationGlucagon‐Like Peptide‐1: Regulation of Insulin Secretion and Therapeutic Potential
Gromada, J., Brock, B., Schmitz, O., & Rorsman, P. (2004) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2004.t01-1-pto950502.x · Cited by 105
“1993) and inhibits food intake (Flint et al. 1998).”
BackgroundGlucagon-related peptide 1 (GLP-1): hormone and neurotransmitter
Larsen, P. J., & Holst, J. J. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2004.08.026 · Cited by 125
Self-citationSemaglutide delays 4‐hour gastric emptying in women with polycystic ovary syndrome and obesity
Jensterle, M., Ferjan, S., Ležaič, L., Sočan, A., Goričar, K., Zaletel, K., & Janez, A. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14944 · Cited by 102
Exposure-response analyses of liraglutide 3.0 mg for weight management
Wilding, J. P. H., Overgaard, R. V., Jacobsen, L. V., Jensen, C. B., & le Roux, C. W. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12639 · Cited by 102
Gut hormone co-agonists for the treatment of obesity: from bench to bedside
Nogueiras, R., Nauck, M. A., & Tschöp, M. H. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00812-z · Cited by 102
Metadata
- Authors
- Flint, A., Raben, A., Astrup, A., & Holst, J. J.
- Affiliations
- University of Copenhagen (DK)
- Venue
- Journal of Clinical Investigation
- Published
- 1998-02-01
- Volume
- 101
- Issue
- 3
- Pages
- 515-520
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC508592
- OpenAlex
- W1975756049
- Cited by
- 1,402
- References
- 40
- Citations by year
- 2026: 37 · 2025: 55 · 2024: 62 · 2023: 33 · 2022: 55 · 2021: 53 · 2020: 49 · 2019: 44 · 2018: 52 · 2017: 49 · 2016: 54 · 2015: 59 · 2014: 64 · 2013: 74 · 2012: 72
- FWCI
- 9.31
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Sundhed og Sygdom, Det Frie Forskningsråd
- Medical Research Council
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- glucagon-like peptide-1, satiety, appetite, energy intake, insulin, glucagon, blood glucose, appetite regulation, intravenous infusion
- MeSH terms
- Adult, Appetite, Appetite Depressants, Appetite Regulation, Blood Glucose, Energy Intake, Glucagon, Humans, Insulin, Male, Pain Measurement, Peptide Fragments, Protein Precursors, Satiation, Cross-Over Studies, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.